Aboujaoude E, Barry JJ, Gamel N (2009) Memantine augmentation in treatment-resistant obsessive–compulsive disorder: an open- label trial. J Clin Psychopharmacol 29:51–55
Abramowitz JS, Taylor S, McKay D (2009) Obsessive–compulsive disorder. Lancet 374:491–499
Amiel JM, Mathew SJ (2007) Glutamate and anxiety disorders. Curr Psychiatry Rep 9:278–283
Anthony EW, Nevins ME (1993) Anxiolytic-like effects of N-methyl- D -aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 250:317–324
Boyce-Rustay JM, Holmes A (2006) Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31:2405– 2414
Campeau S, Miserendino MJ, Davis M (1992) Intra-amygdala infusion of the N-methyl- D -aspartate receptor antagonist AP5 blocks acquisition but not expression of fear-potentiated startle to an auditory conditioned stimulus. Behav Neurosci 106:569–574
Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G,
Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58:424–428
Dunn RW, Corbett R, Fielding S (1989) Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 169:1–10
Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL (1991) Actions of D -cycloserine at the N-methyl- D -aspartate-associated glycine receptor site in vivo. Neuropharmacology 30:1167–1171
Fendt M, Koch M, Schnitzler HU (1996) NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response. Eur J Pharmacol 318:1–6
Feusner JD, Kerwin L, Saxena S, Bystritsky A (2009) Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 42:81–93
Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, Cohen T (2002) Pilot-controlled trial of D -cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 5:301–307
Ho YJ, Hsu LS, Wang CF, Hsu WY, Lai TJ, Hsu CC, Tsai YF (2005) Behavioral effects of D -cycloserine in rats: the role of anxiety level. Brain Res 1043:179–185
Hood WF, Compton RP, Monahan JB (1989) D -cycloserine: a ligand for the N-methyl- D -aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91–95
Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529–531
Kalueff A, Nutt DJ (1996) Role of GABA in memory and anxiety. Depress Anxiety 4:100–110
Karcz-Kubicha M, Jessa M, Nazar M, Pla  ́nik A, Hartmann S, Parsons CG, Danysz W (1997) Anxiolytic activity of glycine-B antagonists and partial agonists–no relation to intrinsic activity in the patch clamp. Neuropharmacology 36:1355–1367
Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl- D -aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319–1328
Kew JN, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179:4–29
Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241:835–837
Kleckner NW, Dingledine R (1989) Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on N-methyl- D aspartate receptors. Mol Pharmacol 36:430–436
Kłodzi  ́ska A, Chojnacka-W  ́jcik E (2000) Anticonflict effect of the glycine B receptor partial agonist, D -cycloserine, in rats. Pharma- cological analysis. Psychopharmacology (Berl) 152:224–228
Kotli  ́ska J, Liljequist S (1998) A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701, 324. Psychopharmacology (Berl) 135:175–181
Krystal JH, D’Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, Abi-Saab W, Madonick S (1999) NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 7:125–143
Lipman JJ, Spencer PS (1980) Rapid intracerebroventricular injection assisted by an automatic syringe. J Pharmacol Methods 4:327– 333
Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92:180–185
Lydiard RB (2003) The role of GABA in anxiety disorders. J Clin Psychiatry 64(Suppl 3):21–27
Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM (2005) Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162:2379–2381
Nemeroff CB (2003) The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37:133– 146
Nutt DJ, Malizia AL (2001) New insights into the role of the GABA A -benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390–396
Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11:523–569
Pellow S (1986) Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? Methods Find Exp Clin Pharmacol 8:557–565
Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167
Pła  ́nik A, Pałejko W, Nazar M, Jessa M (1994) Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 4:503–512
Poleszak E, Szewczyk B, K  ̨dzierska E, Wla  ́ P, Pilc A, Nowak G (2004) Antidepressant- and anxiolytic-like activity of magne- sium in mice. Pharmacol Biochem Behav 78:7–12
Poleszak E, Wla  ́ P, Wr  ́bel A, Fidecka S, Nowak G (2008) NMDA/ glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep 60:655–663
Przegali  ́ski E, Tatarczy  ́ska E, Chojnacka-W  ́jcik E (1998) Anxiolytic- and antidepressant-like effects of an antagonist at glycine B receptors. Pol J Pharmacol 50:349–354
Przegali  ́ski E, Tatarczy  ́ska E, Chojnacka-W  ́jcik E (2000) The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology 39:1858–1864
Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D -cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61:1136–1144
Sharma AC, Kulkarni SK (1993) Evidence for benzodiazepine receptor interaction with MK 801 in anxiety related behaviour in rats. Indian J Exp Biol 31:191–193
Sieghart W (1995) Structure and pharmacology of gamma-aminobu- tyric acid A receptor subtypes. Pharmacol Rev 47:181–234
Sieghart W, Fuchs K, Tretter V, Ebert V, Jechlinger M, Hoger H, Adamiker D (1999) Structure and subunit composition of GABA A receptors. Neurochem Int 34:379–385
Stahl SM (2002) Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 63:756–757
Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167:127–135
Trullas R, Jackson B, Skolnick P (1989) Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine- insensitive glycine receptors. Pharmacol Biochem Behav 34:313–316
Trullas R, Folio T, Young A, Miller R, Boje K, Skolnick P (1991) 1- Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol 203:379–385
Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999) International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long- term treatment of anxiety disorders. J Clin Psychopharmacol 19:23S–29S
Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990) D -cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510:158–160
Willetts J, Balster RL, Leander JD (1990) The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423–428
Wood PL, Emmett MR, Rao TS, Mick S, Cler J, Iyengar S (1989) In vivo modulation of the N-methyl- D -aspartate receptor complex by D -serine: potentiation of ongoing neuronal activity as evidenced by increased cerebellar cyclic GMP. J Neurochem 53:979–981